The group extensively investigates molecular mechanisms involved in the onset and progression of cancer, in particular Acute Myeloid Leukemias, Breast Cancer and Melanoma. Points of particular interest are the study of chromatin modifications and modifiers, metabolism and DNA replication. The experimental methodology ranges from mouse models (primary xenotransplants and genetically modified mice) to clinical and epidemiological data. In recent years the group has extensively applied high throughput RNAi screenes and clonal tracking via viral barcoding to characterize cancer-initiating cells and unbiasedly identify driver and targetable genes in vivo (Bossi et al Cancer Discovery 2016). The successful candidate is expected to identify a primary area of interest but also integrate with other ongoing research projects in the group.
The candidate shall operate within the IFOM-IEO-IIT campus, within a large and expanding bioinformatics community. State-of-the-art facilities for sequencing are available (Illumina and ION Torrent instruments). The institute has also access to the Oxford Nanopore MinIon Access Program for single-molecule nanopore sequencing, providing a rare opportunity to develop methodologies for a platform that is not yet commercially available.